ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01282463
Recruitment Status : Completed
First Posted : January 25, 2011
Last Update Posted : May 25, 2015
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2015
  Actual Study Completion Date : March 2015
  Certification/Extension First Submitted : May 8, 2015